Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: A study of the UK
Abstract
Background
Vaccines for COVID-19 represent a major breakthrough. However, worries about adverse effects led to vaccine hesitancy in some people. On the other hand, as COVID-19 may be associated with various sequelae, vaccination may protect against such sequelae via prevention of infections and severe disease.
Methods
We leveraged the UK-Biobank (UKBB) and studied associations of at least one dose of COVID-19 vaccination (BioNTech-BNT162b2 or Oxford-AstraZeneca-ChAdOx1) with short-term hospitalizations from cardiovascular and other selected diseases ( N =393,544; median follow-up = 54 days among vaccinated). Multivariable Cox and Poisson regression analyses were performed. We also performed adjustment using prescription-time distribution matching (PTDM) and prior-event rate ratio (PERR). PERR minimizes unmeasured confounding by comparing event hazards before introduction of vaccination.
Results
We observed that COVID-19 vaccination(at least one dose), when compared to no vaccination, was associated with reduced short-term risks of hospitalizations from stroke(hazard ratio[HR]=0.178, 95% CI: 0.127-0.250, P= 1.50e-23), venous thromboembolism (VTE) (HR=0.426, CI: 0.270-0.673, P= 2.51e-4), dementia(HR=0.114, CI: 0.060-0.216; P= 2.24e-11), non-COVID-19 pneumonia(NCP) (HR=0.108, CI: 0.080-0.145; P= 2.20e-49), coronary artery disease (CAD) (HR=0.563, CI: 0.416-0.762; P= 2.05e-4), chronic obstructive pulmonary disease (COPD) (HR=0.212, CI: 0.126-0.357; P= 4.92e-9), type-2 diabetes (T2DM) (HR=0.216, CI: 0.096-0.486, P= 2.12e-4), heart failure (HR=0.174, CI: 0.118-0.256, P= 1.34e-18) and renal failure (HR=0.415, CI: 0.255-0.677, P= 4.19e-4), based on Cox regression models. Among the above results, reduced hospitalizations for stroke, heart failure, NCP and dementia were consistently observed across all analyses, including regression/PTDM/PERR.
Conclusions
Taken together, this study provides further support to the safety and benefits of COVID-19 vaccination, and such benefits may extend beyond reduction of infection risk or severity per se. However, causal relationships cannot be concluded and further studies are required to verify the findings.
Related articles
Related articles are currently not available for this article.